Abstract
Glioblastoma is one of the most malignant tumors in the central nervous system, which the conventional therapeutic modalities fail to cure the disease but improve the treatment outcome slightly. In the past decades, immune checkpoint blockade (ICB) and cytokine-regulated immunotherapy have ushered in a new era for glioblastoma treatment. However, the immunosuppressive tumor microenvironment hinders and opposites the therapeutic outcomes. Therefore, the increased importance and necessary for better modality in urgent. Moreover, many novel methods and strategies are searching for more effectively therapeutic outcomes. In this study, the glioblastoma cells derived extracellular vesicles (EVs) were adopted as a delivery platform for the chemotherapy agent (doxorubicin, Dox), gene editing platform of CD47 downregulation and IL-9 overexpression (EVs@Dox/sgCD47/IL-9), due to its excellent blood brain barrier (BBB) crossing rate and specifically targeting capability. The as-prepared EVs@Dox/sgCD47/IL-9 was capable to deliver the Dox and gene editing platform into glioblastoma tissue and was assimilated by cancer cells efficiently, where the Dox induce the immunogenic cell death (ICD) of glioblastoma cells, the CRISPR-Cas9 platform down-regulated the expression of CD47 and the over-expression system up-regulated the expression of IL-9, both enhanced the immunity of biological system. Collectively, EVs@Dox/sgCD47/IL-9 demonstrated remarkable anti-tumor effects and reshaped the immunosuppressive tumor microenvironment that polarized the tumor-associated macrophages and activated CD8+ T cells with good biosafety. Thus, it establishes a strong foundation for the development of more effective strategies against glioblastoma.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call